Howe, Charles L., Rachel A. Bergstrom, and Bruce F. Horazdovsky. "SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL." Neurology 73.15 (2009): 1247-1248. Web. 07 Dec. 2021.